arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Maze Therapeutics, Inc.

MAZE
$28.07 ▼ -0.35 (-1.21%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
2 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Maze Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -40.3% ↘
FCF / Share $-2.62 ↘
Trailing P/E —
Price / Book 3.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

2-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-131.12M
↓ -351.0% —
FCF / Share Free cash flow per share
$-2.62
↓ -108.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
20
Cash Quality ↓
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 2 years · 10 quarters